Allogene Therapeutics (ALLO) Operating Margin (2021 - 2024)
Historic Operating Margin for Allogene Therapeutics (ALLO) over the last 4 years, with Q1 2024 value amounting to 315927.27%.
- Allogene Therapeutics' Operating Margin rose 143793900.0% to 315927.27% in Q1 2024 from the same period last year, while for Dec 2024 it was 1241813.64%, marking a year-over-year decrease of 8968273200.0%. This contributed to the annual value of 1241813.64% for FY2024, which is 8968273200.0% down from last year.
- According to the latest figures from Q1 2024, Allogene Therapeutics' Operating Margin is 315927.27%, which was up 143793900.0% from 405280.95% recorded in Q4 2023.
- In the past 5 years, Allogene Therapeutics' Operating Margin registered a high of 2.26% during Q4 2021, and its lowest value of 405280.95% during Q4 2023.
- Moreover, its 4-year median value for Operating Margin was 286345.45% (2023), whereas its average is 232707.56%.
- Examining YoY changes over the last 5 years, Allogene Therapeutics' Operating Margin showed a top increase of 417170500bps in 2022 and a maximum decrease of 2000000000bps in 2022.
- Allogene Therapeutics' Operating Margin (Quarter) stood at 2.26% in 2021, then plummeted by -16431036bps to 370750.0% in 2022, then dropped by -9bps to 405280.95% in 2023, then increased by 22bps to 315927.27% in 2024.
- Its Operating Margin was 315927.27% in Q1 2024, compared to 405280.95% in Q4 2023 and 286345.45% in Q3 2023.